Phocas Financial Corp. Has $3.76 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Phocas Financial Corp. lessened its position in Exelixis, Inc. (NASDAQ:EXEL) by 5.9% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 144,782 shares of the biotechnology company’s stock after selling 9,057 shares during the period. Phocas Financial Corp.’s holdings in Exelixis were worth $3,757,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. V Square Quantitative Management LLC acquired a new position in shares of Exelixis during the 3rd quarter worth about $30,000. Park Place Capital Corp bought a new stake in shares of Exelixis in the second quarter valued at approximately $45,000. GAMMA Investing LLC grew its stake in shares of Exelixis by 107.9% in the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 1,041 shares during the last quarter. EntryPoint Capital LLC grew its stake in shares of Exelixis by 537.2% in the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 1,746 shares during the last quarter. Finally, Capital Performance Advisors LLP bought a new position in Exelixis during the third quarter worth $61,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Stock Up 0.2 %

NASDAQ:EXEL opened at $34.52 on Tuesday. The business’s 50-day moving average price is $29.22 and its two-hundred day moving average price is $25.26. The stock has a market cap of $9.86 billion, a P/E ratio of 22.13, a PEG ratio of 0.88 and a beta of 0.51. Exelixis, Inc. has a twelve month low of $19.20 and a twelve month high of $36.60.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The business had revenue of $539.50 million during the quarter, compared to the consensus estimate of $490.31 million. During the same period in the previous year, the firm posted $0.10 earnings per share. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. On average, equities research analysts expect that Exelixis, Inc. will post 1.68 EPS for the current fiscal year.

Insider Activity

In other news, EVP Dana Aftab sold 96,986 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $35.00, for a total value of $3,394,510.00. Following the transaction, the executive vice president now directly owns 498,945 shares in the company, valued at $17,463,075. This trade represents a 16.27 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Jeffrey Hessekiel sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $25.79, for a total transaction of $515,800.00. Following the sale, the executive vice president now directly owns 630,325 shares of the company’s stock, valued at approximately $16,256,081.75. This represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 248,148 shares of company stock valued at $8,042,547. Corporate insiders own 2.85% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on EXEL shares. Guggenheim lifted their target price on Exelixis from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 price target on shares of Exelixis in a report on Tuesday, July 30th. Morgan Stanley lifted their price objective on Exelixis from $26.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, October 11th. BMO Capital Markets upped their target price on shares of Exelixis from $29.00 to $36.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, Bank of America raised their target price on shares of Exelixis from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Exelixis presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.44.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.